|
[1]
|
Li, Y., et al. (2020) Prevalence of Diabetes Recorded in Mainland China Using 2018 Diagnostic Criteria from the Amer-ican Diabetes Association: National Cross Sectional Study. BMJ, 369, Article No. m997. [Google Scholar] [CrossRef] [PubMed]
|
|
[2]
|
Schnurr, T.M., et al. (2020) Obesity, Unfavourable Lifestyle and Genetic Risk of Type 2 Diabetes: A Case-Cohort Study. Diabetologia, 63, 1324-1332. [Google Scholar] [CrossRef] [PubMed]
|
|
[3]
|
Thongnak, L., Pongchaidecha, A. and Lungkaphin, A. (2020) Renal Lipid Metabolism and Lipotoxicity in Diabetes. The American Journal of the Medical Sciences, 359, 84-99. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Rohm, T.V., Meier, D.T., Olefsky, J.M. and Donath, M.Y. (2022) Inflammation in Obesity, Diabetes, and Related Disorders. Immunity, 55, 31-55. [Google Scholar] [CrossRef] [PubMed]
|
|
[5]
|
Wan, H., et al. (2020) Associations between Abdominal Obesi-ty Indices and Diabetic Complications: Chinese Visceral Adiposity Index and Neck Circumference. Cardiovascular Dia-betology, 19, Article No. 118. [Google Scholar] [CrossRef] [PubMed]
|
|
[6]
|
Sjöström, L., et al. (2012) Bariatric Surgery and Long-Term Cardiovascular Events. JAMA, 307, 56-65. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Carlsson, L.M.S., et al. (2017) Long-Term Incidence of Microvascu-lar Disease after Bariatric Surgery or Usual Care in Patients with Obesity, Stratified by Baseline Glycaemic Status: A Post-Hoc Analysis of Participants from the Swedish Obese Subjects Study. The Lancet Diabetes and Endocrinology, 5, 271-279. [Google Scholar] [CrossRef]
|
|
[8]
|
Pontiroli, A.E., et al. (2016) Long-Term Mortality and Inci-dence of Cardiovascular Diseases and Type 2 Diabetes in Diabetic and Nondiabetic Obese Patients Undergoing Gastric Banding: A Controlled Study. Cardiovascular Diabetology, 15, Article No. 39. [Google Scholar] [CrossRef] [PubMed]
|
|
[9]
|
Pontiroli, A.E., et al. (2019) Incidence of Diabetes Mellitus, Car-diovascular Diseases, and Cancer in Patients Undergoing Malabsorptive Surgery (Biliopancreatic Diversion and Bilioin-testinal Bypass) vs Medical Treatment. Obesity Surgery, 29, 935-942. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
Pontiroli, A.E., et al. (2020) Bariatric Surgery, Compared to Medical Treatment, Reduces Morbidity at All Ages but Does Not Reduce Mortality in Patients Aged < 43 Years, Espe-cially if Diabetes Mellitus Is Present: A Post Hoc Analysis of Two Retrospective Cohort Studies. Acta Diabetologica, 57, 323-333. [Google Scholar] [CrossRef] [PubMed]
|
|
[11]
|
Song, P., Yu, J., Chan, K.Y., Theodoratou, E. and Rudan, I. (2018) Prevalence, Risk Factors and Burden of Diabetic Retinopathy in China: A Systematic Review and Meta-Analysis. Journal of Global Health, 8, Article ID: 010803. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
Lin, S., Gupta, B., James, N. and Ling, R.H. (2017) Visual Impair-ment Certification due to Diabetic Retinopathy in North and Eastern Devon. Acta Ophthalmologica, 95, e756-e762. [Google Scholar] [CrossRef] [PubMed]
|
|
[13]
|
Eid, S., et al. (2019) New Insights into the Mechanisms of Diabetic Com-plications: Role of Lipids and Lipid Metabolism. Diabetologia, 62, 1539-1549. [Google Scholar] [CrossRef] [PubMed]
|
|
[14]
|
Chew, E.Y., et al. (1996) Association of Elevated Serum Lipid Levels with Retinal Hard Exudate in Diabetic Retinopathy: Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Archives of Ophthalmology, 114, 1079-1084. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Mooradian, A.D. (2009) Dyslipidemia in Type 2 Di-abetes Mellitus. Nature Reviews Endocrinology, 5, 150-159. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Zhu, W., et al. (2018) Association of Obesity and Risk of Diabetic Retinopathy in Diabetes Patients: A Meta-Analysis of Prospective Cohort Studies. Medicine, 97, e11807. [Google Scholar] [CrossRef]
|
|
[17]
|
Han, X., et al. (2022) Differential Effect of Generalized and Abdominal Obesity on the Development and Progression of Diabetic Retinopathy in Chinese Adults with Type 2 Diabe-tes. Frontiers in Medicine, 9, Article 774216. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
Kahn, H.S. (2005) The “Lipid Accumulation Product” Performs Better than the Body Mass Index for Recognizing Cardiovascular Risk: A Population-Based Comparison. BMC Cardio-vascular Disorders, 5, Article No. 26. [Google Scholar] [CrossRef] [PubMed]
|
|
[19]
|
Li, X., et al. (2021) Association among Lipid Accumulation Product, Chinese Visceral Obesity Index and Diabetic Retinopathy in Patients with Type 2 Diabetes: A Cross-Sectional Study. Diabetes, Metabolic Syndrome and Obesity, 14, 4971-4979. [Google Scholar] [CrossRef]
|
|
[20]
|
Cheung, N., Mitchell, P. and Wong, T.Y. (2010) Diabetic Retinopathy. Lancet, 376, 124-136. [Google Scholar] [CrossRef]
|
|
[21]
|
Kowluru, R.A., Mishra, M., Kowluru, A. and Kumar, B. (2016) Hyperlipidemia and the Development of Diabetic Retinopathy: Comparison between Type 1 and Type 2 Animal Models. Metabolism: Clinical and Experimental, 65, 1570-1581. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kowluru, R.A. (2019) Mitochondrial Stability in Diabetic Reti-nopathy: Lessons Learned from Epigenetics. Diabetes, 68, 241-247. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Kowluru, R.A., Kowluru, A., Mishra, M. and Kumar, B. (2015) Oxidative Stress and Epigenetic Modifications in the Pathogenesis of Diabetic Retinopathy. Progress in Retinal and Eye Research, 48, 40-61. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Kowluru, R.A., et al. (2014) TIAM1-RAC1 Signalling Ax-is-Mediated Activation of NADPH Oxidase-2 Initiates Mitochondrial Damage in the Development of Diabetic Retinopa-thy. Diabetologia, 57, 1047-1056. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Kowluru, R.A. (2020) Retinopathy in a Diet-Induced Type 2 Dia-betic Rat Model and Role of Epigenetic Modifications. Diabetes, 69, 689-698. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Chew, E.Y., et al. (2014) The Effects of Medical Management on the Pro-gression of Diabetic Retinopathy in Persons with Type 2 Diabetes: The Action to Control Cardiovascular Risk in Diabe-tes (ACCORD) Eye Study. Ophthalmology, 121, 2443-2451. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
Keech, A.C., et al. (2007) Effect of Fenofibrate on the Need for Laser Treatment for Diabetic Retinopathy (FIELD Study): A Randomised Controlled Trial. Lancet, 370, 1687-1697. [Google Scholar] [CrossRef]
|
|
[28]
|
Alicic, R.Z., Rooney, M.T. and Tuttle, K.R. (2017) Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clinical Journal of the American Society of Nephrology, 12, 2032-2045. [Google Scholar] [CrossRef]
|
|
[29]
|
Hukportie, D.N., et al. (2021) Anthropometric Measures and Incident Diabetic Nephropathy in Participants with Type 2 Diabetes Mellitus. Frontiers in Endocrinology, 12, Article 706845. [Google Scholar] [CrossRef] [PubMed]
|
|
[30]
|
Gao, S., Zhang, H., Long, C. and Xing, Z. (2021) Asso-ciation between Obesity and Microvascular Diseases in Patients with Type 2 Diabetes Mellitus. Frontiers in Endocrinol-ogy, 12, Article 719515. [Google Scholar] [CrossRef] [PubMed]
|
|
[31]
|
Adiels, M., Olofsson, S.O., Taskinen, M.R. and Borén, J. (2008) Overproduction of Very Low-Density Lipoproteins Is the Hallmark of the Dyslipidemia in the Metabolic Syndrome. Ar-teriosclerosis, Thrombosis, and Vascular Biology, 28, 1225-1236. [Google Scholar] [CrossRef]
|
|
[32]
|
Okubo, K., et al. (2004) Abnormal HDL Apolipoprotein A-I and A-II Kinetics in Hemodialysis Patients: A Stable Isotope Study. Journal of the American Society of Nephrology, 15, 1008-1015. [Google Scholar] [CrossRef]
|
|
[33]
|
Vaziri, N.D. (2016) Disorders of Lipid Metabolism in Nephrotic Syndrome: Mechanisms and Consequences. Kidney International, 90, 41-52. [Google Scholar] [CrossRef] [PubMed]
|
|
[34]
|
Kaysen, G.A. (2011) New Insights into Lipid Metabolism in Chronic Kidney Disease. Journal of Renal Nutrition, 21, 120-123. [Google Scholar] [CrossRef] [PubMed]
|
|
[35]
|
Bosmans, J.L., et al. (2001) Oxidative Modification of Low-Density Lipoproteins and the Outcome of Renal Allografts at Years. Kidney International, 59, 2346-2356. [Google Scholar] [CrossRef] [PubMed]
|
|
[36]
|
Malle, E., et al. (1997) Immunological Evidence for Hypo-chlorite-Modified Proteins in Human Kidney. The American Journal of Pathology, 150, 603-615.
|
|
[37]
|
Scheuer, H., et al. (2000) Oxidant Stress in Hyperlipidemia-Induced Renal Damage. American Journal of Physiology-Renal Physiology, 278, F63-F74. [Google Scholar] [CrossRef]
|
|
[38]
|
Bermúdez-López, M., et al. (2017) New Per-spectives on CKD-Induced Dyslipidemia. Expert Opinion on Therapeutic Targets, 21, 967-976. [Google Scholar] [CrossRef] [PubMed]
|
|
[39]
|
Drüeke, T.B., et al. (2001) Role of Oxidized Low-Density Lipoprotein in the Atherosclerosis of Uremia. Kidney International, 78, S114-S119. [Google Scholar] [CrossRef] [PubMed]
|
|
[40]
|
Lee, H.S. (1999) Oxidized LDL, Glomerular Mesangial Cells and Collagen. Diabetes Research and Clinical Practice, 45, 117-122. [Google Scholar] [CrossRef]
|
|
[41]
|
Sastre, C., et al. (2013) Hyperlipidemia-Associated Renal Damage Decreases Klotho Expression in Kidneys from ApoE Knockout Mice. PLOS ONE, 8, e83713. [Google Scholar] [CrossRef] [PubMed]
|
|
[42]
|
Muñoz-García, B., et al. (2009) Tumor Necrosis Factor-Like Weak Inducer of Apoptosis (TWEAK) Enhances Vascular and Renal Damage Induced by Hyperlipidemic Diet in Ap-oE-Knockout Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 29, 2061-2068. [Google Scholar] [CrossRef]
|
|
[43]
|
Opazo-Ríos, L., et al. (2020) Lipotoxicity and Diabetic Nephropathy: Novel Mechanistic Insights and Therapeutic Opportunities. International Journal of Molecular Sciences, 21, Article No. 2632. [Google Scholar] [CrossRef] [PubMed]
|
|
[44]
|
Hager, M.R., Narla, A.D. and Tannock, L.R. (2017) Dyslipidemia in Patients with Chronic Kidney Disease. Reviews in Endocrine & Metabolic Disorders, 18, 29-40. [Google Scholar] [CrossRef] [PubMed]
|
|
[45]
|
Ferrara, D., Montecucco, F., Dallegri, F. and Carbone, F. (2019) Impact of Different Ectopic Fat Depots on Cardiovascular and Metabolic Diseases. Journal of Cellular Physiology, 234, 21630-21641. [Google Scholar] [CrossRef] [PubMed]
|
|
[46]
|
Edgerton, D.S., et al. (2017) Insulin’s Direct Hepatic Effect Explains the In-hibition of Glucose Production Caused by Insulin Secretion. JCI Insight, 2, e91863. [Google Scholar] [CrossRef] [PubMed]
|
|
[47]
|
Fineberg, D., Jandeleit-Dahm, K.A. and Cooper, M.E. (2013) Dia-betic Nephropathy: Diagnosis and Treatment. Nature Reviews Endocrinology, 9, 713-723. [Google Scholar] [CrossRef] [PubMed]
|
|
[48]
|
de Vries, A.P., et al. (2014) Fatty Kidney: Emerging Role of Ectopic Lipid in Obesity-Related Renal Disease. The Lancet Diabetes and Endocrinology, 2, 417-426. [Google Scholar] [CrossRef]
|
|
[49]
|
DeZwaan-McCabe, D., et al. (2017) ER Stress Inhibits Liver Fatty Acid Oxidation while Unmitigated Stress Leads to Anorexia-Induced Lipolysis and Both Liver and Kidney Steato-sis. Cell Reports, 19, 1794-1806. [Google Scholar] [CrossRef] [PubMed]
|
|
[50]
|
Jonker, J.T., et al. (2018) Metabolic Imaging of Fatty Kidney in Diabesity: Validation and Dietary Intervention. Nephrology Dialysis Transplantation, 33, 224-230. [Google Scholar] [CrossRef] [PubMed]
|
|
[51]
|
Praga, M. and Morales, E. (2017) The Fatty Kidney: Obesity and Renal Disease. Nephron, 136, 273-276. [Google Scholar] [CrossRef] [PubMed]
|
|
[52]
|
Foster, M.C., et al. (2011) Fatty Kidney, Hypertension, and Chronic Kid-ney Disease: The Framingham Heart Study. Hypertension, 58, 784-790. [Google Scholar] [CrossRef]
|
|
[53]
|
Xu, S., Zhang, X. and Liu, P. (2018) Lipid Droplet Proteins and Metabolic Diseases. Elsevier Biochimica et Biophysica Acta (BBA)-Molecular Basis of Disease, 1864, 1968-1983. [Google Scholar] [CrossRef] [PubMed]
|
|
[54]
|
Ashcroft, F.M., Rohm, M., Clark, A. and Brereton, M.F. (2017) Is Type 2 Diabetes a Glycogen Storage Disease of Pancreatic β Cells? Cell Metabolism, 26, 17-23. [Google Scholar] [CrossRef] [PubMed]
|
|
[55]
|
Bandet, C.L., Tan-Chen, S., Bourron, O., Le Stunff, H. and Haj-duch, E. (2019) Sphingolipid Metabolism: New Insight into Ceramide-Induced Lipotoxicity in Muscle Cells. Internation-al Journal of Molecular Sciences, 20, Article No. 479. [Google Scholar] [CrossRef] [PubMed]
|
|
[56]
|
Petersen, M.C. and Shulman, G.I. (2017) Roles of Diacylglycerols and Ceramides in Hepatic Insulin Resistance. Trends in Pharmacological Sciences, 38, 649-665. [Google Scholar] [CrossRef] [PubMed]
|
|
[57]
|
Afshinnia, F., et al. (2019) Increased Lipogenesis and Impaired β-Oxidation Predict Type 2 Diabetic Kidney Disease Progression in American Indians. JCI Insight, 4, e130317. [Google Scholar] [CrossRef] [PubMed]
|
|
[58]
|
Tofte, N., et al. (2019) Lipidomic Analysis Reveals Sphingomyelin and Phosphatidylcholine Species Associated with Renal Impairment and All-Cause Mortality in Type 1 Diabetes. Scien-tific Reports, 9, Article No. 16398. [Google Scholar] [CrossRef] [PubMed]
|
|
[59]
|
Tanaka, Y., et al. (2011) Fenofibrate, a PPARα Agonist, Has Renoprotective Effects in Mice by Enhancing Renal Lipolysis. Kidney International, 79, 871-882. [Google Scholar] [CrossRef] [PubMed]
|
|
[60]
|
Wang, C., et al. (2018) GLP-1 Receptor Agonist Ameliorates Obesi-ty-Induced Chronic Kidney Injury via Restoring Renal Metabolism Homeostasis. PLOS ONE, 13, e0193473. [Google Scholar] [CrossRef] [PubMed]
|
|
[61]
|
Jayachandran, M., et al. (2019) Isoquercetin Upregulates Anti-oxidant Genes, Suppresses Inflammatory Cytokines and Regulates AMPK Pathway in Streptozotocin-Induced Diabetic Rats. Chemico-Biological Interactions, 303, 62-69. [Google Scholar] [CrossRef] [PubMed]
|
|
[62]
|
Kim, M.Y., et al. (2013) Resveratrol Prevents Renal Lipotoxicity and Inhibits Mesangial Cell Glucotoxicity in a Manner Dependent on the AMPK-SIRT1-PGC1α Axis in db/db Mice. Dia-betologia, 56, 204-217. [Google Scholar] [CrossRef] [PubMed]
|
|
[63]
|
Ogawa, K., et al. (2004) History of Obesity as a Risk Factor for Both Carotid Atherosclerosis and Microangiopathy. Diabetes Research and Clinical Practice, 66, S165-168. [Google Scholar] [CrossRef] [PubMed]
|
|
[64]
|
Wolf, D. and Ley, K. (2019) Immunity and Inflammation in Atherosclerosis. Circulation Research, 124, 315-327. [Google Scholar] [CrossRef]
|
|
[65]
|
Weber, C., Badimon, L., Mach, F. and van der Vorst, E.P.C. (2017) Therapeutic Strategies for Atherosclerosis and Atherothrombosis: Past, Present and Future. Thrombosis and Haemostasis, 117, 1258-1264. [Google Scholar] [CrossRef]
|
|
[66]
|
Fredman, G.and Tabas, I. (2017) Boosting Inflammation Resolution in Atherosclerosis: The Next Frontier for Therapy. The American Journal of Pathology, 187, 1211-1221. [Google Scholar] [CrossRef] [PubMed]
|
|
[67]
|
Avogaro, A. and de Kreutzenberg, S.V. (2005) Mechanisms of Endothelial Dysfunction in Obesity. Clinica Chimica Acta, 360, 9-26. [Google Scholar] [CrossRef] [PubMed]
|
|
[68]
|
La Sala, L., Prattichizzo, F. and Ceriello, A. (2019) The Link be-tween Diabetes and Atherosclerosis. European Journal of Preventive Cardiology, 26, 15-24. [Google Scholar] [CrossRef] [PubMed]
|
|
[69]
|
Wiebe, N., Stenvinkel, P. and Tonelli, M. (2019) Associations of Chronic Inflammation, Insulin Resistance, and Severe Obesity with Mortality, Myocardial Infarction, Cancer, and Chronic Pulmonary Disease. JAMA Network Open, 2, e1910456. [Google Scholar] [CrossRef] [PubMed]
|
|
[70]
|
王晓霞, 等. 脂肪细胞因子在糖尿病发生发展过程中作用机制的研究进展[J]. 中国现代医生, 2020, 58(3): 183-186.
|
|
[71]
|
袁颜玉, 郭青玉, 邵加庆. 脂肪因子与糖尿病内皮功能障碍的研究进展[J]. 医学研究生学报, 2021, 34(3): 293-298. [Google Scholar] [CrossRef]
|
|
[72]
|
Neves, K.B., et al. (2018) Chemerin Receptor Block-ade Improves Vascular Function in Diabetic Obese Mice via Redox-Sensitive and Akt-Dependent Pathways. American Journal of Physiology-Heart and Circulatory Physiology, 315, H1851-H1860. [Google Scholar] [CrossRef] [PubMed]
|
|
[73]
|
Zhang, B.-H., Wang, W., Wang, H., Yin, J. and Zeng, X.-J. (2013) Promoting Effects of the Adipokine, Apelin, on Diabetic Nephropathy. PLOS ONE, 8, e60457. [Google Scholar] [CrossRef] [PubMed]
|